Patients with schizophrenia have a lot of life-changing consequences when they are being treated properly, and these are only amplified when the patient goes untreated, explained Megan Ehret, PharmD, of University of Maryland, School of Pharmacy.
There are life-changing aspects to schizophrenia that are amplified when patients are untreated for the condition, explained Megan Ehret, PharmD, MS, BCPP, professor and codirector of the Mental Health Program, University of Maryland, School of Pharmacy.
Ehret discussed schizophrenia management strategies in a session at AMCP Nexus, held October 14-17 in Las Vegas, Nevada.
This transcript has been lightly edited for clarity.
Transcript
How does a schizophrenia diagnosis affect the day-to-day lives of patients both when they are being treated properly and when they are not?
When we think about the treatment of schizophrenia, there are life-changing consequences just to the illness itself. There is a lot more social isolation. There can be stigma and reduced aspects and quality of life. You may be less likely to have a partner, less likely to maybe accomplish college or other aspects of life.
When it goes untreated, those are just amplified. The patient may be hearing voices. They may be paranoid about things around them. Ultimately, each of those things can affect different parts of their lives. They also, additionally, have the potential with schizophrenia to have a reduced life expectancy because of some of the aspects of the illness.
When schizophrenia is appropriately treated, and we use an effective medication, people can go on to have the same quality of life as someone without schizophrenia. They are able to attend college, able to obtain employment, able to have families and function. I think Bethany's story [from the AMCP Nexus session] really highlights how when she found the most effective treatment, she was able to continue on and finish her college degree and complete the quality of life that she was looking for.
It's unfortunate many of our treatments also decrease the life expectancy, because of the adverse effects that can occur from those. So, it's important that when patients are engaged in treatment that they continue to have monitoring so that we can make sure that those things are all adequately monitored and watched for.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen